about
miRNA Deregulation in Cancer Cells and the Tumor MicroenvironmentThe ZNF304-integrin axis protects against anoikis in cancerAntagonism of tumoral prolactin receptor promotes autophagy-related cell death.Notch3 pathway alterations in ovarian cancer.Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancerAutocrine effects of tumor-derived complement.Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer.Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER.Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers.MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancerTherapeutic silencing of KRAS using systemically delivered siRNAs.XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.Paraneoplastic thrombocytosis in ovarian cancer.Erythropoietin Stimulates Tumor Growth via EphB4.Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis.Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal TransitionIntegrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancerAdrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.ATP11B mediates platinum resistance in ovarian cancer.FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma.Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.Tumour angiogenesis regulation by the miR-200 family.Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis.
P50
Q27025496-BA6C051E-AA4F-4FCC-A0B7-6D8F0B237D93Q28115264-DF69DC7A-42A8-4B68-B61F-CFDCF917BABFQ30579272-DDF470FD-EF8E-4AAD-8CCD-D176E615D828Q33758223-3F66D687-FFC5-47FB-ABB1-FA0E5B2F02BDQ33774648-2B4133CB-EA5B-4286-8046-468F81D8019AQ33855860-D19E8E37-70B7-4C1E-BDDD-C09496048D0DQ33875597-3EB84C09-D7B4-466C-91F3-DFBAA414A4E5Q33956803-7A0B7D8B-2247-450B-8EAC-51967E7A6379Q33989948-43ABB805-2CCA-4B64-96AE-1255FF8CE745Q34433163-4AFF0E05-1D4B-4668-B42F-7CA5B8FC9B9BQ34628919-C467D0F3-B356-455B-990B-19ED4E8BED34Q34664892-A971B46A-1FB7-4F88-8525-83B92D1DD2C7Q34718013-5B088AB8-5CB1-463E-89D2-869B7EC48D67Q35559932-4E18067A-3B11-4F95-A527-880FAFD500B6Q35602930-56B6E920-1DCE-4CEB-BF8B-EC21CE2098A5Q35691011-EEE63981-32E0-48C1-A03E-186983084573Q35812402-7D33CAA6-C7B7-4773-8F22-746A60B3BB09Q36275814-C82FFDC8-4B82-4CF8-B0B5-EB1407873D37Q36405508-2B65534E-0CB3-4DB8-AE08-0102109F202FQ36495124-5E421423-C29A-4254-B591-3D21C1BD3473Q36702185-E4633C51-3F27-43BC-A61A-65693063DB25Q36759360-7B7E1750-A5FA-4D76-9A4A-F891AE519AE8Q36768803-535402BA-EE6A-4B61-AE48-563422B82020Q36793431-4D7ECAAE-829B-4F3C-820D-AA2FB4E53591Q36867341-D120C36E-B0D1-4EFE-B06A-89CBDE0E81CAQ36939981-7801816E-559F-4602-A082-E05A90A4E655Q36971300-B964D37A-3253-455F-9F42-1BEE1E964334Q37523569-72DD7058-7446-451A-B74C-5C1D5EAC4CD2Q37684642-92375EEC-859E-44E6-A06A-70D63A6FF2C5Q37701960-D05D09BB-FB53-4E86-AE5F-0A81AE414ACB
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Rajesha Rupaimoole
@ast
Rajesha Rupaimoole
@en
Rajesha Rupaimoole
@es
Rajesha Rupaimoole
@nl
type
label
Rajesha Rupaimoole
@ast
Rajesha Rupaimoole
@en
Rajesha Rupaimoole
@es
Rajesha Rupaimoole
@nl
prefLabel
Rajesha Rupaimoole
@ast
Rajesha Rupaimoole
@en
Rajesha Rupaimoole
@es
Rajesha Rupaimoole
@nl
P106
P31
P496
0000-0002-4795-7921